Abstract: This study evaluates the enzyme inhibitory and immunomodulatory activities of the lichen specific depsidone, lobaric acid. Lobaric acid was extracted with methanol from Heterodermia sp. found in Labukelle, Sri Lanka with a yield of 0.67 %. It was subjected to enzyme inhibition assays using acetyl and butyryl-cholinesterase, phosphodiesterase, β-glucuronidase, α-glucosidase and urease. In the β -glucuronidase inhibitory activity it showed an IC 50 value of 3.28 ± 0.05 µM, which was significantly lower than that of the standard, D-saccharic acid 1, 4-lactone (IC 50 = 48.4 ± 1.2 µM). Lobaric acid showed a significant inhibition of phosphodiesterase enzyme with an IC 50 = 313.7 ± 2.2, when compared with the two standards EDTA (IC 50 = 274.0 ± 0.1 µM) and cysteine (IC 50 = 748.0 ± 0.1 µM). Lobaric acid showed a moderate actyl and butyryl -cholinesterase inhibitory activity while it showed no activity against the enzymes α-glucosidase and urease.
INTRODUCTION
and selective serine threonine protein kinase (PLK1) inhibitory activity. Lobaric acid inhibits the 5-lipoxygenase pathway by inhibiting the formation of cysteinyl -leukotrines as determined by enzyme immunoassay (Gissurarson et al., 1997) . The antimitotic activity of lobaric acid has also been studied and it has been shown to inhibit the polymerization of tubulin (Morita et al., 2009 (2) been reported that lobaric acid elicit contact allergy in sensitive persons (Thune & Solberg, 1980) .
In this study, the pharmacological potential of lobaric acid, particularly its immunomodulatory and inhibitory activities against β -glucuronidase, acetyl -and butyrylcholinesterases, phosphodiesterase, α-glucosidase, and urease enzymes are reported.
METHODS AND MATERIALS
Manually cleaned, air-dried and crushed lichen specimens of a Heterodermia sp. collected from Labukelle, Sri Lanka were sequentially extracted with CH 2 Cl 2 followed by MeOH. Lobaric acid was isolated with a yield of 0.67 % from the MeOH extracts when fractionated via silica gel column using hexane/CH 2 Cl 2 to CH 2 Cl 2 /MeOH as solvents. The dentification of the compound was carried out by using spectral data and its comparison with the reported data (Gonzilez et al., 1992) .
Lobaric acid was evaluated for its α-glucosidase inhibitory activity using the method of Oki et al. (2000) and against the urease enzyme using the indophenols method (Weatherburn, 1967) .
Lobaric acid was screened over a range of concentrations (3.1 -50 µg/mL) for its oxidative burst inhibitory potential. The measurement of chemiluminescence was employed to investigate the different kinds of reactive oxygen species (OH, O -2 and H 2 O 2 ). Luminol-enhanced chemiluminescence assay was performed as described by Helfand et al. (1982) . Briefly, whole blood neutrophils and polymorphonuclear leukocytes (PMNs) were suspended in Hank's balance salt solution (HBSS) with calcium and magnesium salts and incubated with lobaric acid for 30 min. To each well, serum opsonized zymosan (Saccharomyces cerevisiae origin) was added, followed by the addition of luminol (3-aminophthalhydrazide), and then HBSS to adjust the final volume to 0.2 mL. HBSS was used as a control. Chemiluminescence peaks were recorded with a luminometer.
RESULTS AND DISCUSSION
Cholinesterase inhibitors are used for the management of Alzheimer's disease. Lobaric acid showed moderate inhibition against acetyl-cholinesterase with an IC 50 value of 26.86 ± 0.9 µM and butyryl-cholinesterase with an IC 50 value of 36.76 ± 0.8 µM, when compared to the standard gallanthamine (AChE: 0.50 ± 0.01 µM and BChE: 8.50 ± 0.01 µM). It has been reported that acetylated derivatives of depsidones isolated from Lobaria pulmonaria (L.) Hoffm. (Lobariaceae) possess moderate acetyl-cholinesterase inhibitory activity (Mortia et al., 2009 ). This is the first report on AChE and BChE inhibitory activity of lobaric acid.
In certain diseases such as cancer, inflammatory joint disease, some hepatic diseases and AIDS, the activity of β-glucuronidase increases. An IC 50 value of 3.28 ± 0.05 µM was observed, which is 12 fold more potent than the standard D-saccharic acid 1,4 -lactone (IC 50 = 48.4 ± 1.25 µM).
Many β -glucuronidase inhibitors such as 8 -hydroxytricetin-7-glucuronide, isovitexin, trihydroxypipecolic acid and scoparic acid A and C, Laspartic acid, tectorigenin and benzothiazoles have been isolated from different plants and some are used clinically (Khan et al., 2002) . However, there are no reports of β -glucuronidase inhibitory activity of compounds isolated from lichens.
To determine the inhibitory activity of lobaric acid on acetyl and butyryl-cholinesterases enzymes, electric-eel acetyl-cholinesterase (AChE, EC 3.1.1.7) and horse serum butyryl-cholinesterase (BChE, EC 3.1.1.8) were used. The inhibition was measured using the spectrophotometric method developed by Ellman et al. (1961) .
β-Glucuronidase inhibitory activity was determined by measuring the absorbance of p-nitrophenol at 405 nm, formed from the substrate p-nitrophenyl -β-D-glucuronide on addition of β-glucuronidase in the presence of lobaric acid (Khan et al., 2002) .
Phosphodiesterases enzyme inhibitory activity was measured by a spectrophotometric method using bis-(p-nitropheny1) phosphate as chromogenic substrate, which was added to a mixture containing a buffer, phosphodiesterase enzyme and the test compound lobaric acid. The release of p-nitrophenol was measured at 410 nm. Lobaric acid did not show α-glucosidase inhibitory activity or any significant inhibition against the urease enzyme.
Immunomodulators are substances capable of interacting with the immune system to up-regulate or down-regulate specific aspects of the host response. Due to the broad application of their action, immunomodulators are becoming very popular in the global natural product based health industry (Yeap et al., 2011) . Various disease conditions such as infections, organ transplant rejection, cancer, rheumatoid arthritis, and systemic lupus erythematosus are currently treated with immunomodulating agents (Long et al., 2011) . Different immunomodulatory agents have been screened from a variety of plants, including the lichen Thamnolia vermicularis var. subuliformis (Omarsdottir et al., 2007) . Lobaric acid was screened over a range of concentrations (3.1-50 µg/mL) for its oxidative burst inhibitory potential. It suppressed both the myeloperoxidase dependant and myeloperoxidase independent ROS production with PMNs at the lowest concentration tested (3.1 µg/mL), when compared with standards ibuprofen and sodium diethyldithiocarbamatetrihydrate (Table 1) .
CONCLUSION
Although acetyl and butyryl-cholinesterases inhibitory activities of acetylated and diacytylated depsidones have been reported (Pejin et al., 2012) , this is the first report of these activities of lobaric acid. However, lobaric acid did not show any inhibitory potential against α-glucosidase or urease enzymes. In the β-glucuronidase enzyme inhibitory assay, lobaric acid has shown 12 times higher activity than the available standard D-saccharic acid 1,4-lactone further indicating the pharmacological potential of lobaric acid as a lead compound. Even though a few heteroglycans isolated from the lichen Thamnolia vermicularis var. subuliformis (Omarsdottir et al., 2007) have shown potential immunomodulatory activity, this is the first report of the promising immunomodulatory activity of a lichen depsidone. The results presented above make lobaric acid with highly diverse functional groups, such as three carbonyls in the form of keto, ester and acid, phenolic OH and an ether group, an excellent candidate for future studies with structural optimization. 
